BACKGROUND: Anxious depression, defined as MDD with high levels of anxiety symptoms, has been associated with lower rates of antidepressant response and remission as well as greater chronicity, suicidality and antidepressant side-effect burden. The primary aim of this study was to assess the effectiveness of cognitive therapy (CT) alone or in combination with medications for anxious versus non-anxious depression. METHODS: We assessed the STAR(⁎)D study participants who were partial or non-responders to citalopram. Subjects were then either switched (n=696) to a new antidepressant or to CT alone, or they were kept on citalopram and augmented (n=577) with another antidepressant or CT. We compared response and remission rates, across treatment conditions, between those who met criteria for anxious depression and those who did not. RESULTS: Those with anxious depression had significantly lower remission rates based on the QIDS, whether assigned to switch or augmentation, compared to those with non-anxious depression. Those with anxious depression, compared to those without, had significantly lower response rates based on the QIDS only in the switch group. There was no significant interaction between anxious depression and treatment assignment. LIMITATIONS: Limitations include the use of citalopram as the only Level 1 pharmacotherapy and medication augmentation option, the relatively small size of the CT arms, use of depression-focused CT rather than anxiety-focused CT, and focus on acute treatment outcomes. CONCLUSIONS: Individuals with anxious depression appear to experience higher risk of poorer outcome following pharmacotherapy and/or CT after an initial course of citalopram and continued efforts to target this challenging form of depression are needed.
BACKGROUND:Anxious depression, defined as MDD with high levels of anxiety symptoms, has been associated with lower rates of antidepressant response and remission as well as greater chronicity, suicidality and antidepressant side-effect burden. The primary aim of this study was to assess the effectiveness of cognitive therapy (CT) alone or in combination with medications for anxious versus non-anxious depression. METHODS: We assessed the STAR(⁎)D study participants who were partial or non-responders to citalopram. Subjects were then either switched (n=696) to a new antidepressant or to CT alone, or they were kept on citalopram and augmented (n=577) with another antidepressant or CT. We compared response and remission rates, across treatment conditions, between those who met criteria for anxious depression and those who did not. RESULTS: Those with anxious depression had significantly lower remission rates based on the QIDS, whether assigned to switch or augmentation, compared to those with non-anxious depression. Those with anxious depression, compared to those without, had significantly lower response rates based on the QIDS only in the switch group. There was no significant interaction between anxious depression and treatment assignment. LIMITATIONS: Limitations include the use of citalopram as the only Level 1 pharmacotherapy and medication augmentation option, the relatively small size of the CT arms, use of depression-focused CT rather than anxiety-focused CT, and focus on acute treatment outcomes. CONCLUSIONS: Individuals with anxious depression appear to experience higher risk of poorer outcome following pharmacotherapy and/or CT after an initial course of citalopram and continued efforts to target this challenging form of depression are needed.
Authors: Jon S Novick; Jonathan W Stewart; Stephen R Wisniewski; Ian A Cook; Radmila Manev; Andrew A Nierenberg; Jerrold F Rosenbaum; Kathy Shores-Wilson; G K Balasubramani; Melanie M Biggs; Sid Zisook; A John Rush Journal: J Clin Psychiatry Date: 2005-08 Impact factor: 4.384
Authors: Ellen Frank; David J Kupfer; Daniel J Buysse; Holly A Swartz; Paul A Pilkonis; Patricia R Houck; Paola Rucci; Danielle M Novick; Victoria J Grochocinski; Deborah M Stapf Journal: Am J Psychiatry Date: 2007-05 Impact factor: 18.112
Authors: Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Erica M Richards; Daniel C Mathews; David A Luckenbaugh; Dawn F Ionescu; Rodrigo Machado-Vieira; Mark J Niciu; Wallace C Duncan; Neal M Nolan; Jose A Franco-Chaves; Thomas Hudzik; Carla Maciag; Shuang Li; Alan Cross; Mark A Smith; Carlos A Zarate Journal: Psychopharmacology (Berl) Date: 2016-01-04 Impact factor: 4.530
Authors: Dawn F Ionescu; Richard C Shelton; Lee Baer; Kathryn H Meade; Michaela B Swee; Maurizio Fava; George I Papakostas Journal: Int Clin Psychopharmacol Date: 2016-11 Impact factor: 1.659
Authors: Robert M Carney; Kenneth E Freedland; Brian C Steinmeyer; Eugene H Rubin; Michael W Rich Journal: J Psychosom Res Date: 2016-07-19 Impact factor: 3.006
Authors: Hannah E Berg; Elizabeth D Ballard; David A Luckenbaugh; Allison C Nugent; Dawn F Ionescu; Carlos A Zarate Journal: Compr Psychiatry Date: 2016-06-14 Impact factor: 3.735
Authors: Sandra M Meier; Liselotte Petersen; Manuel Mattheisen; Ole Mors; Preben B Mortensen; Thomas M Laursen Journal: Lancet Psychiatry Date: 2015-05-14 Impact factor: 27.083